Incidence and clinical characteristics of nonmelanoma skin cancers among Hispanic and Asian patients in the US: A 5-year, single institution retrospective review

2015 ◽  
Vol 72 (5) ◽  
pp. AB186
Keyword(s):  
Retrospective Review ◽  
Clinical Characteristics ◽  
Single Institution ◽  
Asian Patients ◽  
Skin Cancers ◽  
The Us ◽  
Nonmelanoma Skin Cancers

Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers

2013 ◽  
Vol 17 (3) ◽  
pp. 173-179 ◽  
Author(s):  
Aditya K. Gupta ◽  
Maryse Paquet
Keyword(s):  
Safety Data ◽  
Mechanisms Of Action ◽  
Scientific Meeting ◽  
Ingenol Mebutate ◽  
Actinic Keratoses ◽  
Skin Cancers ◽  
The Us ◽  
New Treatment ◽  
Skin Conditions ◽  
Nonmelanoma Skin Cancers

Background: A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration. Objective: To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate. Methods: The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009–2011) and the Annual Meeting of the American Academy of Dermatology (2009–2012) were also searched. Results: Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate. Conclusion: Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.

Sign in / Sign up

Export Citation Format

Share Document